Euroapi reports a net loss of -189.7 million euros for 2023, compared with -15 million in 2022, and a core EBITDA of 93.1 million, representing a margin of 9.2% versus 12.3% the previous year.

The latter was penalized by less favorable absorption of fixed costs and inflation, while sales for the supplier of active pharmaceutical ingredients rose by 3.8% to 1.01 billion euros (+3.1% at constant exchange rates).

For 2024, Euroapi anticipates a core EBITDA margin of between 6 and 9%, as well as a decline in sales of between 4 and 7% on a comparable basis, due in particular to lower sales to Sanofi.

Copyright (c) 2024 CercleFinance.com. All rights reserved.